Background: There is uncertainty about the level of utilization and expenditure for medicines in the European Union (EU), making assessment of their impact on public health difficult. Our aim is to develop indicators to monitor price, expenditure and utilization of medicinal products in the EU, so as to facilitate comparisons. Methods: There are four major tasks. Task 
More than 100,000 medicinal products are marketed in the European Union at a total cost of 100 billion Euro per year.
1 This large utilization of medicines and expenditure has a major impact on public health in the following ways: • They bring benefits to patients through their intended therapeutic effects: i.e. improving or preventing diseases and relieving symptoms.
• They may cause adverse effects, accounting for as much as 10% of all hospital admissions in some surveys. There are also other associated adverse effects arising from poor use, including medication errors, poor quality of prescribing by doctors, and poor compliance with medicines by patients. These may be harmful directly, or indirectly by waste of money or other limited health care resources.
• Medicines account for a substantial portion of health expenditure (up to 20-21% in Spain and France), and although often valuable, there may be an opportunity cost if the expenditure could be used in other ways to improve public health to a greater extent. Furthermore, pharmaceutical expenditure is rising faster than any other area of health care and this is a source of concern to governments, which strive to maintain equitable access to medicines for the population at an affordable cost.
• Utilization of medicines has a large environmental impact because users excrete metabolites and/or unmodified medicines. As of 2000, more than 80 medicines from a wide array of therapeutic classes have been detected in the environment, at concentrations similar to that of pesticides. The risk to the environment or human health of this chronic exposure has never been assessed. • Europe is a major manufacturer and exporter of medicines (a positive trade balance of about 9.2 billion Euro in 1995), with attendant benefits of employment and industrial and technology development. The exact impact on public health of medicines use and the government expenditure on prescriptions (for branded, generic or even over-the-counter medicines) is difficult to assess, in part because of uncertainty about the extent of such utilization and expenditure. Although comparative figures are available from different sources (e.g. OECD, IMS) the methods by which these data were collected and exact definitions and limits of what was measured are not always clear. Our aim in establishing the EURO-MED-STAT project is to develop a set of indicators, to be integrated into the EU Public Health Information Network (EUPHIN), for monitoring price, state expenditure and utilization of medicinal products in the EU member states. The monitoring of price and utilization in a standardized manner could then be used by each EU member state, allowing better comparison between countries and allowing each country to benchmark its performance against others. This study follows on from a related study to evaluate availability of medicines across the EU. 4 The aim of this paper is to present the protocol of the EURO-MED-STAT project, to provide some preliminary data from the ongoing project and discuss some methodological problems in comparing national data.
METHODS
A collaboration of academics and government agencies was formed to undertake the project (appendix). The project was broken into four different tasks.
• Task 1: To produce an inventory of data sources and a survey of available data in each EU Member State on medicine utilization in the community and in hospital, medicine expenditure and medicine prices. • Task 2: To assess the reliability of the data and its comparability between countries: the data are to be collected by defined daily dose (DDD) and medicines classified by ATC code. Key questions on utilization are whether the data covers all the country or only regions, whether both community and hospital data are available, what the sources of such data were (wholesalers, pharmacies, prescribers), whether the data covers only reimbursed medicines or all products (including vitamins and herbal products), and whether they cover only medicines subject to prescription or also self-medication products; and an assessment of the quality of the data, its reliability and availability. Key questions on price and expenditure data are: definition of price (ex-factory, wholesaler, pharmacy, state reimbursed); retail pharmacy price and hospital price; and private spending versus public spending.
• Task 3: To develop Standard Operating Procedure (SOPs) for data management (collection, validation and comparison) . SOPs are essential to overcome the difficulties arising from the differences among national health systems, in the classification of medicinal products and in recording utilization and expenditure. We used the ATC/DDD methodology 5 to organise raw data and to structure the analyses by therapeutic classes. The European Standard for Medicinal product identification (ENV 12610) 6 by the European Committee for Standardization (CEN) will be used as a standard for describing medicinal products and their packages. A set of utilization, cost and expenditure indicators derived from the available validated data will then be produced for data comparison. A key point will be to establish the aims of each indicator and its intended audience/target group. Each indicator will therefore be clearly defined (objective, definition, description, rationale and data collection). The SOPs will also define the confidentiality and accessibility level of the data.
• Task 4: To pool and compare the validated data accord-I ing to the established indicators.
We chose cardiovascular medicines as an example to test these systems and therefore also sought the corresponding utilization and expenditure data. These were selected because of the public health importance of cardiovascular disease and to parallel other EU public health projects on morbidity (EUROCISS 7 ).
RESULTS
Preliminary results of tasks 1 and 2 are now available, and we illustrate them and the developing standard operating procedures (task 3) by applying the methods to an area of cardiovascular therapy (task 4). The major data sources used, selected after careful analysis from a list of 72, are shown in DDD imply clinical equivalence, and so to add up a total of DDDs for all statins as in figure 1 may be excessively simplistic and must not be over-interpreted. Although we wish to classify medicines by ATC code, in practice different countries may use different versions of the code or may even have created their own codes, e.g. for panthetine which is classed in ATC code officially released by the Oslo Centre as Al 1HA32 (vitamins) but in Italy and Spain is reclassified based on its use as C10AX. The value for DDD may change between some versions of the code, although the WHO generally avoids this. Finally, we must consider the implications of differences in utilization in the different countries. For instance in relation to statin prescribing, do the high levels in Scandinavian countries relate to morbidity or to the fact that doctors are more aware and informed on the benefits of statins because the landmark 4S study was carried out there? And do the low levels in Italy relate to the virtues of a Mediterranean diet and low morbidity, or to the use of low doses rather than to small numbers of patients treated or a higher discontinuation rate? Use of other lip id reducing medicines than the statins (listed in table 2) may also explain some of the differences. Our final data will not answer all these questions but will prompt a further examination in each country to question why these differences exist and what the optimal case in the interests of public health should be. Another aim of the EUROMED-STAT project is to collect data on prices and this illustrates further difficulties. Comparing price is not simple. First there are issues of converting different currencies (less of a problem since the introduction of the euro). Second, there are widely recognized differences in purchasing power parity between countries both generally and more specifically for pharmaceuticals. Third, there are a number of prices which might be compared, e.g. ex factory, wholesaler, ex pharmacy or the price reimbursed by the state. All of these would have value to different stakeholders, though data on all are not readily available. Even to settle on pharmacy retail price, the most widely available, is problematic -in some countries this includes a mark up for the pharmacist, but not in others, or it may include value added tax at varying rates. The total cost of medicines to a third party payer may be less than the sum of the retail pharmacy costs since in some countries, e.g. the UK, the state pays only a discounted fee to the pharmacist. Nevertheless if we aim to look at European differences pharmacy retail price has the advantage, as compared to ex-factory price, to represent all the components of the system, including differences in distribution costs. Finally, the 'price' may be a myth" -national policy may fix a reference price, or may control the price or the true cost in other, more indirect, ways, for instance by volume/price negotiations in France or by the Pharmaceutical Pricing Regulatory Scheme in the UK. An example of the effects of this last scheme relevant to the example shown here is the flat pricing structure of statins in the UK -i.e. simvastatin costs the same per tablet regardless of dose and as a result, costs 0.95 Euro/DDD if prescribed as 20 mg tablets, but only 0.25 Euro if prescribed as 80 mg tablets. In comparing price across countries, we may also be forced to view only those items which are mutually available across all EU countries -our previous work suggests that this is as low as 7% of all available active ingredients, and if we have to limit our study still further not just to active ingredients but to identical packs by the same manufacturer, and for instance exclude consideration of local generic products, the value of the data would be greatly diminished. These problems will limit our ability to meet our objective of comparing prices, but as with many health service research projects, the availability of data may force a change in the originally planned objectives. Despite the limitations arising from these difficulties and uncertainties, we believe the data from this project, when complete, will be of value because of the information it will provide, the questions it will raise, and because of the insights it will give in a key area of health care and health care spending. Our data will also provide key denominators to help interpret adverse medicine reaction rates, or rates and trends in cardiovascular disease for instance. Our data will be of value because of the transparency in its collection, a factor often missed in data from other sources. Finally the project will be useful as it will explore methods and create standardized operating procedures that can be extended to other areas of pharmaceutical utilization and expenditure.
CONCLUSIONS EURO-MED-STAT aims to produce a set of specific indicators for monitoring the use of medicines and related expenditure across the EU member states. The wide differences between national systems make this a difficult objective but the quality of our data, and the transparency in their collection, will be superior to any previously collect in this area. A standardized mean of monitoring medicine utilization and expenditure internationally offers several advantages from a public health perspective.
Appendix The EURO-MED-STAT Group
Making comparable information publicly available and so increasing transparency in this sector where wide financial interests play an important role, is in itself useful. In addition, good quality data will allow benchmarking between countries in expenditure and utilization which may lead to improvements in the quality of pharmaceutical care and therapeutic outcome, increasing benefits and reducing risks for patients, and enhancing the efficiency of the national pharmaceutical systems.
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